United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 50 mg - acarbose tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. acarbose tablets are contraindicated in patients with known hypersensitivity to the drug. acarbose tablets are also contraindicated in patients with diabetic ketoacidosis or cirrhosis. acarbose tablets are also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, acarbose tablets are contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 50 mg - acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. acarbose is contraindicated in patients with known hypersensitivity to the drug. acarbose is contraindicated in patients with diabetic ketoacidosis or cirrhosis. acarbose is also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, acarbose is contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 25 mg - acarbose tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. acarbose tablets are contraindicated in patients with known hypersensitivity to the drug. acarbose tablets are contraindicated in patients with diabetic ketoacidosis or cirrhosis. acarbose tablets are also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, acarbose tablets are contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 25 mg - acarbose tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. acarbose tablets are contraindicated in patients with known hypersensitivity to the drug. acarbose tablets are contraindicated in patients with diabetic ketoacidosis or cirrhosis. acarbose tablets are also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, acarbose tablets are contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.

United States - English - NLM (National Library of Medicine)

alvogen, inc. - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 25 mg - acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. acarbose is contraindicated in patients with known hypersensitivity to the drug. acarbose is contraindicated in patients with diabetic ketoacidosis or cirrhosis. acarbose is also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, acarbose is contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 25 mg - acarbose tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. acarbose tablets are contraindicated in patients with known hypersensitivity to the drug and in patients with diabetic ketoacidosis or cirrhosis. acarbose tablets are also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, acarbose tablets are contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.

United States - English - NLM (National Library of Medicine)

virtus pharmaceuticals llc - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 25 mg - acarbose tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. acarbose tablets are contraindicated in patients with known hypersensitivity to the drug. acarbose tablets are contraindicated in patients with diabetic ketoacidosis or cirrhosis. acarbose tablets are also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, acarbose tablets are contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 25 mg - acarbose tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. acarbose tablets are contraindicated in patients with known hypersensitivity to the drug. acarbose tablets are contraindicated in patients with diabetic ketoacidosis or cirrhosis. acarbose tablets are also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, acarbose tablets are contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.

United States - English - NLM (National Library of Medicine)

avkare - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 25 mg - acarbose tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. acarbose tablets are contraindicated in patients with known hypersensitivity to the drug. acarbose tablets are contraindicated in patients with diabetic ketoacidosis or cirrhosis. acarbose tablets are also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, acarbose tablets are contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine. safety and effectiveness of acarbose tablets in pediatric patients have not been established. of the total number of subjects in clinical studies of acarbose tablets in the united states, 27% were 65 and over, while 4% were 75 and over. no overall differences in safety and effectiveness were observed between these subjects and younger subjects. the mean steady-state area under the curve (auc) and maximum concentrations of acarbose were approximately 1.5 times higher in elderly compared to young volunteers; however, these differences were not statistically significant.

United States - English - NLM (National Library of Medicine)

strides pharma science limited - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 25 mg - acarbose tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. acarbose tablets are contraindicated in patients with known hypersensitivity to the drug. acarbose tablets are contraindicated in patients with diabetic ketoacidosis or cirrhosis. acarbose tablets are also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, acarbose tablets are contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.